# Engineered E. coli produces 1.805 g/L of antibiotic Angustmycin A in a 1.2-L bioreactor

- Published: 2026-11-19 22:18 UTC
- Section: Life & Health › Biotechnology
- Tags: Angustmycin A, guvermectin, Escherichia coli cell factory, N-nucleoside antibiotic, de novo biosynthesis from glucose, fed-batch fermentation, pfkA deletion, AgmC solubility, liquid–liquid phase separation, biochemical pesticide
- URL: https://realtech.media/news/rt-21a1b5c5c187487995c78632_engineered_e_coli/

**Researchers built an E. coli strain that makes the N-nucleoside antibiotic Angustmycin A from glucose. A lab-scale fed-batch run reached 1805 mg/L at 96 h.**

![Engineered E. coli produces 1.805 g/L of antibiotic Angustmycin A in a 1.2-L bioreactor](https://realtech.media/media/2026/11/ce3b86f0da13b5b9.jpg)
*Peter grotzinger, Wikimedia Commons, CC BY-SA 3.0*

Researchers have engineered an Escherichia coli strain that produces the N-nucleoside antibiotic Angustmycin A (also known as guvermectin) de novo from glucose, according to a paper in Microbial Cell Factories. [1] In fed-batch fermentation in a 1.2-L bioreactor, the final strain reached 1805 ± 74.1 mg L−1 at 96 h, a volumetric productivity of about 18.8 mg L−1 h−1. [1] The authors describe this as the highest Angustmycin A titer reported to date. [1]

Angustmycin A has broad-spectrum antimicrobial activity and a registered agricultural use as a plant growth-promoting biochemical pesticide. [1] It is still produced mainly by native Streptomyces strains, whose slow growth, long fermentation cycles and limited genetic tractability constrain titer improvement and process development. [1] A fast-growing, genetically flexible host was therefore the goal of the work.

## Four stages of strain engineering

In the first stage, the six-enzyme pathway was consolidated onto a single medium-copy plasmid, and the pfkA gene was deleted to redirect fructose-6-phosphate (F6P) flux. [1] Together these changes raised production from 142 mg L−1 to 649 ± 9.0 mg L−1. [1]

The second stage addressed a bottleneck: pathway analysis identified the solubility of the enzyme AgmC as a primary constraint. [1] Recruiting AgmC into liquid–liquid phase separation condensates, with AgmA co-recruited, raised production to 699 ± 7.2 mg L−1. [1]

The third stage combined orthogonal optimization of cultivation parameters with chromosomal engineering of the gltA 5′-UTR to moderate flux through the TCA cycle. [1] Shake-flask production rose to 1225 ± 12.9 mg L−1. [1]

## Bioreactor result and stated levers

The fourth stage was fed-batch cultivation of the final strain in the 1.2-L bioreactor, which gave the 1805 ± 74.1 mg L−1 figure at 96 h. [1] In extended fed-batch cultivation, the maximum titer was approximately 1.92 g L−1. [1] All results come from laboratory-scale cultivation.

The authors identify two main levers for pathway performance: rewiring F6P flux and mitigating the limited availability of soluble AgmC. [1] They add that combining precursor-flux redistribution with bottleneck-guided enzyme recruitment may serve as a transferable framework for microbial production of related N-nucleoside natural products. [1]

## Sources

1. [Microbial Cell Factories](https://doi.org/10.1186/s12934-026-03136-1)
2. [bioengineer.org](https://bioengineer.org/engineered-escherichia-coli-achieves-record-high-titer-biosynthesis-of-antibiotic-angustmycin-a)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-21a1b5c5c187487995c78632_engineered_e_coli/
